1. Home
  2. DYNX vs INBX Comparison

DYNX vs INBX Comparison

Compare DYNX & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DYNX
  • INBX
  • Stock Information
  • Founded
  • DYNX 2024
  • INBX 2010
  • Country
  • DYNX United States
  • INBX United States
  • Employees
  • DYNX N/A
  • INBX N/A
  • Industry
  • DYNX
  • INBX Biotechnology: Pharmaceutical Preparations
  • Sector
  • DYNX
  • INBX Health Care
  • Exchange
  • DYNX NYSE
  • INBX Nasdaq
  • Market Cap
  • DYNX 221.3M
  • INBX 178.5M
  • IPO Year
  • DYNX 2024
  • INBX 2020
  • Fundamental
  • Price
  • DYNX $10.06
  • INBX $12.96
  • Analyst Decision
  • DYNX
  • INBX Hold
  • Analyst Count
  • DYNX 0
  • INBX 1
  • Target Price
  • DYNX N/A
  • INBX N/A
  • AVG Volume (30 Days)
  • DYNX 13.6K
  • INBX 97.1K
  • Earning Date
  • DYNX 01-01-0001
  • INBX 05-14-2025
  • Dividend Yield
  • DYNX N/A
  • INBX N/A
  • EPS Growth
  • DYNX N/A
  • INBX N/A
  • EPS
  • DYNX N/A
  • INBX 111.58
  • Revenue
  • DYNX N/A
  • INBX $200,000.00
  • Revenue This Year
  • DYNX N/A
  • INBX N/A
  • Revenue Next Year
  • DYNX N/A
  • INBX N/A
  • P/E Ratio
  • DYNX N/A
  • INBX $0.12
  • Revenue Growth
  • DYNX N/A
  • INBX N/A
  • 52 Week Low
  • DYNX $9.78
  • INBX $10.80
  • 52 Week High
  • DYNX $10.48
  • INBX $18.95
  • Technical
  • Relative Strength Index (RSI)
  • DYNX N/A
  • INBX 53.73
  • Support Level
  • DYNX N/A
  • INBX $12.25
  • Resistance Level
  • DYNX N/A
  • INBX $13.88
  • Average True Range (ATR)
  • DYNX 0.00
  • INBX 0.71
  • MACD
  • DYNX 0.00
  • INBX 0.15
  • Stochastic Oscillator
  • DYNX 0.00
  • INBX 69.85

About DYNX DYNAMIX CORP

Dynamix Corp is a blank check company.

About INBX Inhibrx Inc.

Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.

Share on Social Networks: